U.S. District Court allows Provigil reverse payment suits to proceed* On 29 March 2010 the U.S. District Court for the Eastern District of Pennsylvania rejected defendants’ motions to dismiss in suits concerning reverse payment settlements between the brand name manufacturer of the pharmaceutical Provigil (Cephalon, Inc.) and several manufacturers of generic pharmaceuticals. The plaintiffs in the suits – including the Federal Trade Commission (“FTC”) – claim, in particular, that the settlements
The US District Court for the Eastern District of Pennsylvania allows the reverse payment suits to proceed when finding that the agreements extended beyond the scope of the concerned patent (Cephalon)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.